Publication

Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature

Baldwin, D. S., den Boer, J. A., Lyndon, G., Emir, B., Schweizer, E. & Haswell, H., Oct-2015, In : Journal of Psychopharmacology. 29, 10, p. 1047-1060 14 p.

Research output: Contribution to journalReview articleAcademicpeer-review

APA

Baldwin, D. S., den Boer, J. A., Lyndon, G., Emir, B., Schweizer, E., & Haswell, H. (2015). Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature. Journal of Psychopharmacology, 29(10), 1047-1060. https://doi.org/10.1177/0269881115598411

Author

Baldwin, David S. ; den Boer, Johan A. ; Lyndon, Gavin ; Emir, Birol ; Schweizer, Edward ; Haswell, Hannah. / Efficacy and safety of pregabalin in generalised anxiety disorder : A critical review of the literature. In: Journal of Psychopharmacology. 2015 ; Vol. 29, No. 10. pp. 1047-1060.

Harvard

Baldwin, DS, den Boer, JA, Lyndon, G, Emir, B, Schweizer, E & Haswell, H 2015, 'Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature', Journal of Psychopharmacology, vol. 29, no. 10, pp. 1047-1060. https://doi.org/10.1177/0269881115598411

Standard

Efficacy and safety of pregabalin in generalised anxiety disorder : A critical review of the literature. / Baldwin, David S.; den Boer, Johan A.; Lyndon, Gavin; Emir, Birol; Schweizer, Edward; Haswell, Hannah.

In: Journal of Psychopharmacology, Vol. 29, No. 10, 10.2015, p. 1047-1060.

Research output: Contribution to journalReview articleAcademicpeer-review

Vancouver

Baldwin DS, den Boer JA, Lyndon G, Emir B, Schweizer E, Haswell H. Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature. Journal of Psychopharmacology. 2015 Oct;29(10):1047-1060. https://doi.org/10.1177/0269881115598411


BibTeX

@article{3fbfc7f603e34584bf43c649305ef919,
title = "Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature",
abstract = "The aim of this review is to summarise the literature on the efficacy and safety of pregabalin for the treatment of generalised anxiety disorder (GAD). Of 241 literature citations, 13 clinical trials were identified that were specifically designed to evaluate the efficacy and safety of pregabalin in GAD, including 11 randomised double-blind trials and two open-label studies. Pregabalin efficacy has been consistently demonstrated across the licensed dose range of 150-600 mg/day. Efficacy has been reported for pregabalin monotherapy in elderly patients with GAD, patients with severe anxiety, and for adjunctive therapy when added to a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor in patients who have failed to respond to an initial course of antidepressant therapy. The two most common adverse events with pregabalin are somnolence and dizziness, both of which appear to be dose-related. Pregabalin appears to have a low potential for causing withdrawal symptoms when long-term therapy is discontinued; however, tapering over the course of at least one week is recommended. A review of available evidence indicates that pregabalin is a well-tolerated and consistently effective treatment for GAD, with a unique mechanism of action that makes it a useful addition to the therapeutic armamentarium.",
keywords = "Generalised anxiety disorder, pregabalin, efficacy, safety, PLACEBO-CONTROLLED TRIAL, POSTTRAUMATIC-STRESS-DISORDER, OBSESSIVE-COMPULSIVE DISORDER, DOSE-RESPONSE RELATIONSHIP, TERM BENZODIAZEPINE USE, DOUBLE-BLIND, MENTAL-DISORDERS, PHARMACOLOGICAL-TREATMENT, HEALTHY-VOLUNTEERS, MAJOR DEPRESSION",
author = "Baldwin, {David S.} and {den Boer}, {Johan A.} and Gavin Lyndon and Birol Emir and Edward Schweizer and Hannah Haswell",
note = "{\circledC} The Author(s) 2015.",
year = "2015",
month = "10",
doi = "10.1177/0269881115598411",
language = "English",
volume = "29",
pages = "1047--1060",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications Inc.",
number = "10",

}

RIS

TY - JOUR

T1 - Efficacy and safety of pregabalin in generalised anxiety disorder

T2 - A critical review of the literature

AU - Baldwin, David S.

AU - den Boer, Johan A.

AU - Lyndon, Gavin

AU - Emir, Birol

AU - Schweizer, Edward

AU - Haswell, Hannah

N1 - © The Author(s) 2015.

PY - 2015/10

Y1 - 2015/10

N2 - The aim of this review is to summarise the literature on the efficacy and safety of pregabalin for the treatment of generalised anxiety disorder (GAD). Of 241 literature citations, 13 clinical trials were identified that were specifically designed to evaluate the efficacy and safety of pregabalin in GAD, including 11 randomised double-blind trials and two open-label studies. Pregabalin efficacy has been consistently demonstrated across the licensed dose range of 150-600 mg/day. Efficacy has been reported for pregabalin monotherapy in elderly patients with GAD, patients with severe anxiety, and for adjunctive therapy when added to a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor in patients who have failed to respond to an initial course of antidepressant therapy. The two most common adverse events with pregabalin are somnolence and dizziness, both of which appear to be dose-related. Pregabalin appears to have a low potential for causing withdrawal symptoms when long-term therapy is discontinued; however, tapering over the course of at least one week is recommended. A review of available evidence indicates that pregabalin is a well-tolerated and consistently effective treatment for GAD, with a unique mechanism of action that makes it a useful addition to the therapeutic armamentarium.

AB - The aim of this review is to summarise the literature on the efficacy and safety of pregabalin for the treatment of generalised anxiety disorder (GAD). Of 241 literature citations, 13 clinical trials were identified that were specifically designed to evaluate the efficacy and safety of pregabalin in GAD, including 11 randomised double-blind trials and two open-label studies. Pregabalin efficacy has been consistently demonstrated across the licensed dose range of 150-600 mg/day. Efficacy has been reported for pregabalin monotherapy in elderly patients with GAD, patients with severe anxiety, and for adjunctive therapy when added to a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor in patients who have failed to respond to an initial course of antidepressant therapy. The two most common adverse events with pregabalin are somnolence and dizziness, both of which appear to be dose-related. Pregabalin appears to have a low potential for causing withdrawal symptoms when long-term therapy is discontinued; however, tapering over the course of at least one week is recommended. A review of available evidence indicates that pregabalin is a well-tolerated and consistently effective treatment for GAD, with a unique mechanism of action that makes it a useful addition to the therapeutic armamentarium.

KW - Generalised anxiety disorder

KW - pregabalin

KW - efficacy

KW - safety

KW - PLACEBO-CONTROLLED TRIAL

KW - POSTTRAUMATIC-STRESS-DISORDER

KW - OBSESSIVE-COMPULSIVE DISORDER

KW - DOSE-RESPONSE RELATIONSHIP

KW - TERM BENZODIAZEPINE USE

KW - DOUBLE-BLIND

KW - MENTAL-DISORDERS

KW - PHARMACOLOGICAL-TREATMENT

KW - HEALTHY-VOLUNTEERS

KW - MAJOR DEPRESSION

U2 - 10.1177/0269881115598411

DO - 10.1177/0269881115598411

M3 - Review article

C2 - 26259772

VL - 29

SP - 1047

EP - 1060

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

IS - 10

ER -

ID: 25349832